Staging of gastric cancers by PET-FAPI
Key facts
- Where
- Montpellier Cedex 5 és Pessac Cedex, FranciaországSee the 2 sites
- Phase
- 2. fázis
Where in Franciaország
- Institut Regional Du Cancer De MontpellierMontpellier Cedex 5, FranciaországToborzás még nem indult
- Centre Hospitalier Universitaire De BordeauxPessac Cedex, FranciaországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire De Bordeaux
- Trial code
- EU 2025-524434-25-00
- Record updated
- 2026. április 30.
- Original description
In the study target population (stage ≥ II gastric adenocarcinomas or signet-ring cells adenocarcinomas of any stage, eligible for curative treatment), estimate the proportion of patients who present an appropriate change of TNM classification following the addition of 68Ga-FAPI-46 PET-CT to the reference examinations, during the initial staging (including laparoscopy)Read full original descriptionShow less
"Contribution of 68Ga-FAPI-46 PET-CT in the initial staging of gastric cancers eligible for curative treatment" "FAPGASTRO"
In the study target population (stage ≥ II gastric adenocarcinomas or signet-ring cells adenocarcinomas of any stage, eligible for curative treatment), estimate the proportion of patients who present an appropriate change of TNM classification following the addition of 68Ga-FAPI-46 PET-CT to the reference examinations, during the initial staging (including laparoscopy)
Inclusion: Gastric cancer: stage ≥ II gastric adenocarcinoma or signet-ring cell adenocarcinoma whatever the stage, potentially requiring curative treatment; Age > 18 years old at time of signed consent; Beneficiary of social security insurance; Signed informed consent by the participant and the investigator.
Exclusion: History of other active cancer; Known contraindication to a PET examination with injection of radiopharmaceuticals (hypersensitivity to the radiopharmaceutical drug and/or excipients); Tumor M+ or with suspicion of distant metastasis on standard assessment; Person deprived of liberty by judicial or administrative decision; Neoadjuvant treatment already started; Pregnant or breastfeeding woman; Woman of childbearing capacity and not benefiting from effective contraception (HAS criterion); Person subject to a legal protection measure or unable to personally give consent; Person in an emergency situation; Exclusion period from another protocol.